NRC Health (NRC)
Market Price (10/25/2026): $21.95 | Market Cap: $485.5 MilSector: Health Care | Industry: Health Care Technology
NRC Health (NRC)
Market Price (10/25/2026): $21.95Market Cap: $485.5 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% Attractive yieldDividend Yield is 2.6% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, and AI in Healthcare Management. | Trading close to highsDist 52W High is -2.9% Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -120% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 33x, P/EPrice/Earnings or Price/(Net Income) is 82x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.1% Key risksNRC key risks include [1] a significant and ongoing earnings contraction cycle, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Attractive yieldDividend Yield is 2.6% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, and AI in Healthcare Management. |
| Trading close to highsDist 52W High is -2.9% |
| Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -120% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 33x, P/EPrice/Earnings or Price/(Net Income) is 82x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.1% |
| Key risksNRC key risks include [1] a significant and ongoing earnings contraction cycle, Show more. |
Qualitative Assessment
AI Analysis | Feedback
NRC Health (NRC) stock has remained largely at the same level since 6/30/2026 because of the following key factors:
1. Balanced fiscal Q2 2026 Performance: NRC Health reported a mixed financial picture for fiscal Q2 2026 (ended June 30, 2026), which was announced on July 28, 2026. While the company achieved a 4% year-over-year revenue increase to $35.4 million and an 11% rise in Total Recurring Contract Value (TRCV) to $151.9 million, indicating strong top-line growth and future revenue potential, it also posted a GAAP net loss of ($3.3) million. The adjusted net income per diluted share of $0.31 significantly beat analyst estimates of ($0.15). This combination of operational strength and a GAAP loss likely led to a neutral investor reaction, preventing significant stock movement.
2. Consistent Analyst Sentiment and Valuation: The stock maintained a relatively stable outlook from analysts during this period. As of October 1, 2026, the sole analyst covering NRC Health had a "Buy" rating and a price target of $26.00, suggesting a potential upside of 22.7% from the stock's price at that time. This target was reaffirmed and raised from $23 to $26 by Citizens on July 29, 2026, following the Q2 earnings report. The consistent target price and sole "Market Outperform" rating by the covering analyst likely contributed to the stock trading within a defined range, as investors had clear, stable expectations.
Show more
NRC Health (NRC) stock has remained largely at the same level since 6/30/2026 because of the following key factors:
1. Balanced fiscal Q2 2026 Performance: NRC Health reported a mixed financial picture for fiscal Q2 2026 (ended June 30, 2026), which was announced on July 28, 2026. While the company achieved a 4% year-over-year revenue increase to $35.4 million and an 11% rise in Total Recurring Contract Value (TRCV) to $151.9 million, indicating strong top-line growth and future revenue potential, it also posted a GAAP net loss of ($3.3) million. The adjusted net income per diluted share of $0.31 significantly beat analyst estimates of ($0.15). This combination of operational strength and a GAAP loss likely led to a neutral investor reaction, preventing significant stock movement.
2. Consistent Analyst Sentiment and Valuation: The stock maintained a relatively stable outlook from analysts during this period. As of October 1, 2026, the sole analyst covering NRC Health had a "Buy" rating and a price target of $26.00, suggesting a potential upside of 22.7% from the stock's price at that time. This target was reaffirmed and raised from $23 to $26 by Citizens on July 29, 2026, following the Q2 earnings report. The consistent target price and sole "Market Outperform" rating by the covering analyst likely contributed to the stock trading within a defined range, as investors had clear, stable expectations.
3. Operational Momentum Offset by Cost Pressures and Leadership Transition: While NRC Health demonstrated robust commercial momentum, including broad-based TRCV growth, a 60% increase in the sales pipeline year-over-year, and higher average deal sizes, these positives were somewhat diluted by ongoing financial headwinds. The company faced high selling, general, and administrative expenses due to increased stock-based compensation, executive salaries, and software costs, which impacted operating income in the first half of fiscal 2026. Additionally, higher long-term debt led to increased interest expense, and the company reported a $12.2 million working-capital deficit as of June 30, 2026. The announced resignation of the CFO and the CEO assuming the interim Principal Financial Officer role, effective October 14, 2026, also introduced an element of uncertainty, balancing the operational successes with financial and leadership considerations.
Show less
Stock Movement Drivers
Fundamental Drivers
The 2.5% change in NRC stock from 6/30/2026 to 10/24/2026 was primarily driven by a 59.6% change in the company's P/E Multiple.| (LTM values as of) | 6302026 | 10242026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.40 | 21.93 | 2.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 139 | 140 | 1.0% |
| Net Income Margin (%) | 6.5% | 4.2% | -35.8% |
| P/E Multiple | 51.6 | 82.4 | 59.6% |
| Shares Outstanding (Mil) | 22 | 22 | -1.0% |
| Cumulative Contribution | 2.5% |
Market Drivers
6/30/2026 to 10/24/2026| Return | Correlation | |
|---|---|---|
| NRC | 2.5% | |
| Market (SPY) | 1.8% | 22.4% |
| Sector (XLV) | 13.0% | 20.0% |
Fundamental Drivers
The 31.2% change in NRC stock from 3/31/2026 to 10/24/2026 was primarily driven by a 219.3% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 10242026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.72 | 21.93 | 31.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 142 | 140 | -1.1% |
| Net Income Margin (%) | 10.0% | 4.2% | -58.0% |
| P/E Multiple | 25.8 | 82.4 | 219.3% |
| Shares Outstanding (Mil) | 22 | 22 | -1.0% |
| Cumulative Contribution | 31.2% |
Market Drivers
3/31/2026 to 10/24/2026| Return | Correlation | |
|---|---|---|
| NRC | 31.2% | |
| Market (SPY) | 17.2% | 10.9% |
| Sector (XLV) | 22.8% | 17.6% |
Fundamental Drivers
The 77.4% change in NRC stock from 9/30/2025 to 10/24/2026 was primarily driven by a 637.0% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 10242026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.36 | 21.93 | 77.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 147 | 140 | -5.1% |
| Net Income Margin (%) | 17.0% | 4.2% | -75.4% |
| P/E Multiple | 11.2 | 82.4 | 637.0% |
| Shares Outstanding (Mil) | 23 | 22 | 2.9% |
| Cumulative Contribution | 77.4% |
Market Drivers
9/30/2025 to 10/24/2026| Return | Correlation | |
|---|---|---|
| NRC | 77.4% | |
| Market (SPY) | 15.0% | 11.1% |
| Sector (XLV) | 30.5% | 9.0% |
Fundamental Drivers
The -46.4% change in NRC stock from 9/30/2023 to 10/24/2026 was primarily driven by a -81.7% change in the company's Net Income Margin (%).| (LTM values as of) | 9302023 | 10242026 | Change |
|---|---|---|---|
| Stock Price ($) | 40.89 | 21.93 | -46.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 152 | 140 | -7.7% |
| Net Income Margin (%) | 22.9% | 4.2% | -81.7% |
| P/E Multiple | 29.1 | 82.4 | 183.6% |
| Shares Outstanding (Mil) | 25 | 22 | 12.3% |
| Cumulative Contribution | -46.4% |
Market Drivers
9/30/2023 to 10/24/2026| Return | Correlation | |
|---|---|---|
| NRC | -46.4% | |
| Market (SPY) | 83.9% | 22.2% |
| Sector (XLV) | 45.8% | 22.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NRC Return | -2% | -8% | 10% | -54% | 10% | 17% | -42% |
| Peers Return | 25% | -35% | -13% | -15% | -34% | -1% | -61% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| NRC Win Rate | 58% | 50% | 33% | 33% | 50% | 70% | |
| Peers Win Rate | 58% | 36% | 42% | 42% | 31% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NRC Max Drawdown | -26% | -24% | -16% | -58% | -45% | -46% | |
| Peers Max Drawdown | -26% | -54% | -44% | -41% | -56% | -37% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HCAT, MDRX, IQV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/23/2026 (YTD)
How Low Can It Go
| Event | NRC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -40.0% | -18.8% |
| % Gain to Breakeven | 66.7% | 23.1% |
| Time to Breakeven | 63 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.1% | -24.5% |
| % Gain to Breakeven | 31.8% | 32.4% |
| Time to Breakeven | 250 days | 427 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -16.4% | -12.2% |
| % Gain to Breakeven | 19.6% | 13.9% |
| Time to Breakeven | 11 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -15.6% | -6.8% |
| % Gain to Breakeven | 18.5% | 7.3% |
| Time to Breakeven | 7 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -37.7% | -0.2% |
| % Gain to Breakeven | 60.5% | 0.2% |
| Time to Breakeven | 1303 days | 1 days |
In The Past
NRC Health's stock fell -40.0% during the 2025 US Tariff Shock. Such a loss loss requires a 66.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NRC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -40.0% | -18.8% |
| % Gain to Breakeven | 66.7% | 23.1% |
| Time to Breakeven | 63 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.1% | -24.5% |
| % Gain to Breakeven | 31.8% | 32.4% |
| Time to Breakeven | 250 days | 427 days |
| 2013 Taper Tantrum | ||
| % Loss | -37.7% | -0.2% |
| % Gain to Breakeven | 60.5% | 0.2% |
| Time to Breakeven | 1303 days | 1 days |
In The Past
NRC Health's stock fell -40.0% during the 2025 US Tariff Shock. Such a loss loss requires a 66.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About NRC Health (NRC)
NRC Health (National Research Corporation) specializes in providing analytics and insights to healthcare organizations, primarily in the United States and Canada. The company's core mission is to help these organizations measure and enhance both the patient and employee experience within their operations. They offer a portfolio of subscription-based solutions that deliver actionable information and analysis to support mission-critical, constituent-related elements.
The company's main products and services encompass a wide range of solutions. These include tools for patient experience measurement, service recovery, care transitions, and health risk assessments to identify and manage at-risk populations. NRC Health also provides employee engagement platforms, reputation management services, and market insights for tracking brand awareness and competitive differentiation. Additionally, they offer transparency solutions to inform consumer decision-making and governance solutions for healthcare boards and executives.
NRC Health primarily serves a diverse clientele within the healthcare sector. Their customers include integrated health systems, post-acute care providers, and payer organizations. By leveraging NRC Health's comprehensive solutions, these clients can effectively segment populations, enhance preventative care, reduce readmissions, improve patient satisfaction, and strengthen their overall brand loyalty and operational governance.
AI Analysis | Feedback
- Qualtrics for healthcare experience management
- Nielsen for healthcare market and brand insights
AI Analysis | Feedback
- Patient Experience Solutions: Provides analytics and tools to measure, enhance, and manage patient and resident experiences, including service recovery and care transitions.
- Employee Engagement Solutions: Offers insights and analytics to measure and improve workforce engagement and satisfaction within healthcare organizations.
- Health Risk Assessment Solutions: Enables healthcare clients to segment populations, identify high-risk individuals, and manage preventive care and wellness programs.
- Market Insights Solutions: Delivers tools for tracking healthcare brand awareness, perception, competitive differentiation, and community segmentation.
- Reputation & Transparency Solutions: Assists healthcare organizations in managing their public reputation and sharing information to inform consumer decision-making.
- Governance Solutions: Provides insights and support for not-for-profit hospital and health system boards of directors, executives, and physician leadership.
AI Analysis | Feedback
NRC Health (symbol: NRC) serves other companies, primarily within the healthcare sector. Based on the provided description, its major customers fall into the following categories:
- Integrated health systems
- Post-acute providers
- Payer organizations
AI Analysis | Feedback
AI Analysis | Feedback
Trent Green, Chief Executive Officer
Trent Green became Chief Executive Officer of NRC Health on June 1, 2025. He brings over 25 years of healthcare leadership experience, having previously served as CEO of One Medical and Chief Operating Officer at Legacy Health. Green is recognized for his expertise in care delivery, digital transformation, and strategic business execution, and was named to the inaugural TIME100 Most Influential People in Health list.
Shane Harrison, Executive Vice President and Chief Financial Officer
Shane Harrison was appointed Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. He possesses over 25 years of experience in corporate finance, investor relations, and strategic transactions. Prior to NRC Health, Harrison was Senior Vice President – Finance and Investor Relations at PowerSchool. His career also includes senior roles at NAVEX Global and various positions, including Interim CFO, at FLIR Systems. He began his career with Deloitte and worked as an investment banker at Lehman Brothers.
Helen Hrdy, Chief Customer Officer
Helen Hrdy has a tenure of over 24 years at NRC Health (as of February 2024). In her role, she has been instrumental in assisting numerous healthcare organizations through the company's Human Understanding approach. She has developed and led multidisciplinary teams with a primary focus on fostering strong partner relationships, expanding her role from Chief Growth Officer to Chief Customer Officer in early 2024.
Jason Hahn, Chief Revenue Officer
Jason Hahn joined NRC Health after leading multiple global revenue organizations, specializing in patient, employee, and financial experience. His prior senior leadership positions include roles at Press Ganey, Perceptyx, and Kaufman Hall/Axiom.
Andy Monnich, Chief Corporate Development Officer
Andy Monnich has over 20 years of experience in product and corporate development across the healthcare, financial services, and education sectors. Before his current role at NRC Health, he served as Chief Strategy Officer at Practicing Excellence. His career also includes consulting and leadership positions at Connect, AEGON, and the Gallup Organization.
AI Analysis | Feedback
The key risks to NRC Health's business are primarily centered around intense market competition and the continuous need for innovation, the critical importance of cybersecurity and data privacy, and the inherent dependence on customer contract renewals within the evolving healthcare industry.
Intense Competition and Need for Innovation: The healthcare analytics and insights market, in which NRC Health operates, is highly competitive with relatively low barriers to entry. The company faces significant competition from existing players, including larger, more resourced entities, as well as new entrants, particularly those leveraging advanced technologies like AI. To maintain and grow its market share and revenue, NRC Health must continuously innovate its subscription-based solutions and market insights offerings, including the development of AI-enabled tools and new product lines. Failure to do so, or the success of competitors' innovations, could lead to pricing pressure, market share losses, and adversely affect operating results.
Cybersecurity and Data Privacy Threats: As a provider of solutions that facilitate the measurement and enhancement of patient and employee experiences, NRC Health collects, processes, and stores highly sensitive data, including Protected Health Information (PHI) and Personally Identifiable Information (PII). This makes the company particularly vulnerable to cybersecurity breaches, data theft, and IT system failures. Any significant security incident, whether internal or involving third-party vendors, could result in substantial financial losses, severe reputational damage, loss of customer trust, and significant regulatory penalties, especially given stringent regulations like HIPAA and state data protection laws.
Dependence on Contract Renewals and Healthcare Industry Trends: NRC Health's business model relies heavily on recurring revenue from subscription-based service agreements with healthcare organizations. Consequently, the company is exposed to risks associated with customer contract non-renewals, pricing pressures, and potential reductions in service scope, which could materially impact its revenues. Furthermore, its performance is closely tied to the broader healthcare industry, which is highly regulated, susceptible to policy changes, consolidation, and economic downturns. Adverse shifts in the healthcare landscape, macroeconomic pressures such as inflation and rising interest rates, or challenges faced by its healthcare clients could negatively affect NRC Health's financial condition and operating results.
AI Analysis | Feedback
AI Analysis | Feedback
NRC Health (symbol: NRC) operates in several key addressable markets across the United States and Canada, providing solutions that enhance patient and employee experiences, manage reputation, and support healthcare governance. The addressable market sizes for their main products and services are outlined below:
- Patient Experience and Engagement Solutions: The North America patient engagement solutions market generated an estimated revenue of USD 12,045.6 million in 2024 and is projected to reach USD 36,042.2 million by 2030, growing at a compound annual growth rate (CAGR) of 20% from 2025 to 2030. Specifically in the U.S., the patient engagement solutions market was valued at USD 7.40 billion in 2025 and is predicted to increase to approximately USD 25.21 billion by 2034, expanding at a CAGR of 14.68% from 2025 to 2034. The North American patient experience (PX) technology market held a significant share, accounting for approximately 44.6% of the global revenue in 2024. The global patient experience technology market is projected to reach USD 1.16 billion by 2030, growing from USD 0.66 billion in 2025 at a CAGR of 11.8%.
- Employee Engagement and Healthcare Workforce Management Solutions: The North America employee engagement software market generated USD 390.8 million in revenue in 2024 and is expected to reach USD 959.4 million by 2030, with a CAGR of 16.1% from 2025 to 2030. North America also held the largest share of the global employee engagement software market in 2023, accounting for over 37%. For healthcare workforce management systems, the U.S. market generated USD 662.8 million in revenue in 2023 and is expected to reach USD 1,513.5 million by 2030, growing at a CAGR of 12.5% from 2024 to 2030.
- Reputation Management and Brand Loyalty Solutions: The U.S. healthcare digital marketing outsourcing market, which includes reputation management, generated USD 3,274.5 million in revenue in 2023 and is projected to reach USD 6,275.8 million by 2030, exhibiting a CAGR of 9.7% from 2024 to 2030. Globally, the online reputation management market was valued at USD 6.88 billion in 2025 and is estimated to grow to USD 14.01 billion by 2031, at a CAGR of 12.59% during the forecast period (2026-2031). North America accounted for 38.20% of the revenue in this market in 2025.
- Care Management and Health Risk Assessment Solutions: The global care management solutions market size was valued at USD 17.07 billion in 2025 and is projected to grow to USD 60.11 billion by 2034, with a CAGR of 15.01% during the forecast period (2026-2034). North America led the global market with the highest market share of 42% in 2025, with its market size reaching USD 5.54 billion in 2025. Health risk assessment solutions are often encompassed within broader digital health and patient engagement offerings. The U.S. digital health market size recorded US$ 88.38 billion in 2025 and is projected to hit nearly US$ 266.5 billion by 2035, with a CAGR of 11.67% throughout the forecast timeline.
- Governance Solutions: The global healthcare information governance solution (IGS) market was valued at USD 18.58 billion in 2024 and is projected to reach USD 63.33 billion by 2033, growing at a CAGR of 14.6% during the forecast period (2025-2033). North America dominates this market, accounting for approximately 45% of the market revenue in 2024. The North America healthcare compliance software market alone accounted for USD 933.4 million in revenue in 2023.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for NRC Health (symbol: NRC) over the next 2-3 years:
- Expansion to new markets: NRC Health plans to expand its geographic reach, specifically targeting select European markets, starting with the UK's National Health Service (NHS) in late 2024. The company aims for 15% of its total revenue to come from outside North America by 2030.
- Launch and growth of new and AI-enabled products and services: The company is making significant investments in research and development, committing 18% of its annual revenue in 2024 to advanced AI and machine learning capabilities. Key innovations include its proprietary 'Predictive Experience' engine, the 'Longitudinal Patient Engagement' platform, and AI-enabled products powered by Huey™ launched in August 2024. Additionally, new AI-powered listening capabilities are in beta for their "Rounding" solution.
- Growth in customers and cross-selling within existing clients: NRC Health is focused on expanding its client base within the U.S. healthcare sector through strategic partnerships and by aggressively cross-selling its integrated patient experience solutions. This strategy targets an estimated $120 million in annual synergies by 2026, partly due to the integration of recent acquisitions. The company's sales team reorganization has led to an 86% year-over-year increase in full-year new sales and improved win rates.
- Strategic acquisitions and integration: Maximizing value from recent strategic acquisitions, such as Nobl in August 2024 (expected to enhance real-time feedback solutions) and a compliance software firm in June 2025, is a key growth strategy. These acquisitions bolster the company's product offerings and facilitate cross-selling opportunities.
- Increasing Total Recurring Contract Value (TRCV): NRC Health has demonstrated consistent sequential growth in its Total Recurring Contract Value (TRCV), reaching over $152 million as of March 4, 2026, an all-time high. This metric is a strong indicator of future revenue, reflecting robust customer retention and the acquisition of new, renewable contracts. The growth in TRCV has been driven by strong sales momentum across both existing and new customers.
AI Analysis | Feedback
Share Repurchases
- NRC Health's Board of Directors authorized a new stock repurchase program of up to $60 million through March 31, 2028.
- In 2025, the company repurchased approximately $10.7 million of common stock.
- In 2024, the company repurchased approximately $33.17 million of common stock.
- In 2022, NRC Health repurchased 744,499 shares for an aggregate of $27.6 million.
Share Issuance
- In 2025, the company generated approximately $3.631 million from share issuance.
- In 2024, the company generated approximately $2.036 million from share issuance.
- In 2023, the company generated approximately $2.76 million from share issuance.
Outbound Investments
- In August 2024, NRC Health acquired Nobl, a leading healthcare rounding technology company. This acquisition aimed to enhance real-time patient and employee feedback solutions and support partners in listening and acting on patient and employee insights.
Capital Expenditures
- In 2025, capital expenditures totaled $10.7 million, focusing on building improvements, furniture, equipment, computer hardware, and software development for Human Understanding® solutions.
- In 2023, the company spent $15.8 million on capital expenditures, primarily for computer software development for Human Understanding solutions and headquarters building renovations.
- In 2022, capital expenditures amounted to $9.8 million, with major allocations to computer software development ($3.6 million) and headquarters building renovations ($5.1 million).
Peer Outperformance in Health Care Technology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 12.8% | 52.4% | 94.7% | CAH 457% · MCK 390% · COR 183% |
| Health Care Services | 20 | 18.5% | 46.9% | 17.1% | HIMS 265% · RDNT 123% · DGX 82% |
| Health Care Facilities | 24 | 2.4% | 21.5% | 6.5% | THC 280% · NHC 278% · ENSG 146% |
| Managed Health Care | 8 | 29.6% | 2.5% | 1.6% | OSCR 82% · HQY 54% · ELV 9% |
| Health Care Equipment | 50 | -1.5% | 7.9% | -13.6% | UFPT 372% · GKOS 298% · TMDX 158% |
| Pharmaceuticals | 61 | -17.5% | 1.8% | -33.6% | LQDA 1088% · KNSA 616% · LLY 447% |
| Health Care Supplies | 11 | 15.9% | -4.2% | -39.6% | LNTH 339% · HAE 65% · MMSI 29% |
| Life Sciences Tools & Services | 109 | -5.8% | -1.1% | -72.7% | MEDP 258% · NTRA 251% · AXGN 168% |
| Biotechnology | 364 | -25.7% | -21.2% | -81.5% | DNTH 1076% · ELVN 1063% · ADMA 734% |
| Health Care Technology ← | 22 | -33.0% | -62.0% | -82.5% | VEEV 1% · DOCS -48% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| National Research Earnings Notes | 12/16/2025 | |
| National Research Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.45 |
| Mkt Cap | 0.5 |
| Rev LTM | 440 |
| Op Inc LTM | -2 |
| FCF LTM | 52 |
| FCF 3Y Avg | 7 |
| CFO LTM | 73 |
| CFO 3Y Avg | 20 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.6% |
| Rev Chg 3Y Avg | 1.5% |
| Rev Chg Q | -2.9% |
| QoQ Delta Rev Chg LTM | -0.8% |
| Op Inc Chg LTM | -27.4% |
| Op Inc Chg 3Y Avg | 23.9% |
| Op Mgn LTM | 3.6% |
| Op Mgn 3Y Avg | 9.2% |
| QoQ Delta Op Mgn LTM | -2.2% |
| CFO/Rev LTM | 18.1% |
| CFO/Rev 3Y Avg | 9.3% |
| FCF/Rev LTM | 13.5% |
| FCF/Rev 3Y Avg | 4.3% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Analytics and insight solutions designed to measure and improve patient and employee experience for | 137 | 143 | 149 | 152 | 148 |
| Total | 137 | 143 | 149 | 152 | 148 |
| $ Mil | 2024 | 2022 |
|---|---|---|
| Analytics and insight solutions designed to measure and improve patient and employee experience for | 35 | 47 |
| Total | 35 | 47 |
| $ Mil | 2024 | 2022 |
|---|---|---|
| Analytics and insight solutions designed to measure and improve patient and employee experience for | 25 | 32 |
| Total | 25 | 32 |
Price Behavior
| Market Price | $21.93 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 05/23/2013 | |
| Distance from 52W High | -2.9% | |
| 50 Days | 200 Days | |
| DMA Price | $20.99 | $18.85 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 4.5% | 16.3% |
| 3M | 1YR | |
| Volatility | 56.8% | 58.1% |
| Downside Capture | 53.80 | 27.56 |
| Upside Capture | 71.64 | 99.71 |
| Correlation (S&P 500) | 21.4% | 10.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.23 | 0.33 | 1.56 | 0.59 | 0.55 | 0.73 |
| Up Beta | 4.85 | 1.15 | 0.80 | -0.05 | -0.08 | 0.74 |
| Down Beta | -0.36 | 0.07 | 5.67 | 1.99 | 0.89 | 0.51 |
| Up Capture | -35% | 36% | 91% | 58% | 92% | 28% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 10 | 20 | 34 | 68 | 135 | 369 |
| Down Capture | 4% | -51% | 108% | 22% | 47% | 102% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 12 | 22 | 30 | 57 | 114 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRC | |
|---|---|---|---|---|
| NRC | 91.0% | 58.1% | 1.33 | - |
| Sector ETF (XLV) | 24.5% | 16.3% | 1.15 | 9.7% |
| Equity (SPY) | 14.8% | 12.7% | 0.80 | 10.7% |
| Gold (GLD) | -2.8% | 28.5% | -0.11 | -17.5% |
| Commodities (DBC) | 52.1% | 20.7% | 1.91 | -16.2% |
| Real Estate (VNQ) | 4.3% | 13.9% | 0.06 | 2.7% |
| Bitcoin (BTCUSD) | -24.8% | 43.5% | -0.54 | 3.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRC | |
|---|---|---|---|---|
| NRC | -10.2% | 43.1% | -0.12 | - |
| Sector ETF (XLV) | 8.7% | 15.3% | 0.37 | 25.4% |
| Equity (SPY) | 12.7% | 17.1% | 0.56 | 25.3% |
| Gold (GLD) | 17.3% | 18.9% | 0.73 | -9.1% |
| Commodities (DBC) | 9.5% | 19.5% | 0.37 | -6.3% |
| Real Estate (VNQ) | 1.1% | 18.9% | -0.05 | 24.3% |
| Bitcoin (BTCUSD) | 5.7% | 51.7% | 0.29 | 13.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRC | |
|---|---|---|---|---|
| NRC | 5.7% | 40.8% | 0.27 | - |
| Sector ETF (XLV) | 11.7% | 16.8% | 0.57 | 35.4% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 38.7% |
| Gold (GLD) | 11.8% | 16.4% | 0.59 | -3.2% |
| Commodities (DBC) | 8.4% | 18.1% | 0.38 | 6.0% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 37.8% |
| Bitcoin (BTCUSD) | 62.4% | 66.2% | 1.02 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 10/19/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/28/2026 | -18.1% | -12.3% | -1.5% |
| 4/28/2026 | -1.8% | 11.3% | 16.7% |
| 2/3/2026 | -19.5% | -29.8% | -40.1% |
| 10/27/2025 | 16.0% | 16.0% | 57.8% |
| 7/28/2025 | -4.8% | -2.0% | 10.4% |
| 4/28/2025 | 9.5% | 17.9% | 22.7% |
| 1/27/2025 | -11.9% | -12.7% | -20.7% |
| 10/25/2024 | 4.5% | 1.1% | 9.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 13 | 13 |
| # Negative | 15 | 11 | 11 |
| Median Positive | 3.6% | 5.1% | 9.4% |
| Median Negative | -4.1% | -4.5% | -9.1% |
| Max Positive | 16.0% | 17.9% | 57.8% |
| Max Negative | -19.5% | -29.8% | -40.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/28/2026 | -18.1% | -12.3% | -1.5% |
| 4/28/2026 | -1.8% | 11.3% | 16.7% |
| 2/3/2026 | -19.5% | -29.8% | -40.1% |
| 10/27/2025 | 16.0% | 16.0% | 57.8% |
| 7/28/2025 | -4.8% | -2.0% | 10.4% |
| 4/28/2025 | 9.5% | 17.9% | 22.7% |
| 1/27/2025 | -11.9% | -12.7% | -20.7% |
| 10/25/2024 | 4.5% | 1.1% | 9.4% |
| 8/6/2024 | -9.5% | -5.1% | -5.0% |
| 5/7/2024 | -16.5% | -12.2% | -24.7% |
| 2/13/2024 | 6.1% | 5.5% | 5.7% |
| 11/8/2023 | -1.5% | 0.1% | 0.9% |
| 8/3/2023 | -2.5% | 0.2% | -4.7% |
| 5/4/2023 | 2.6% | 5.1% | 8.8% |
| 2/16/2023 | -1.1% | -0.7% | -8.9% |
| 11/3/2022 | 2.2% | 8.9% | 12.0% |
| 8/4/2022 | -4.1% | -4.4% | -9.1% |
| 5/5/2022 | -2.6% | -0.7% | 10.8% |
| 2/10/2022 | -5.2% | 3.0% | -5.5% |
| 11/4/2021 | -1.4% | -1.3% | -14.3% |
| 8/5/2021 | 0.4% | 0.2% | 2.4% |
| 5/5/2021 | 3.6% | 4.8% | 5.4% |
| 2/11/2021 | 1.2% | -4.5% | 3.1% |
| 11/3/2020 | -1.7% | 6.3% | -11.0% |
| SUMMARY STATS | |||
| # Positive | 9 | 13 | 13 |
| # Negative | 15 | 11 | 11 |
| Median Positive | 3.6% | 5.1% | 9.4% |
| Median Negative | -4.1% | -4.5% | -9.1% |
| Max Positive | 16.0% | 17.9% | 57.8% |
| Max Negative | -19.5% | -29.8% | -40.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/04/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/05/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/04/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/05/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/06/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
| 06/30/2019 | 08/08/2019 | 10-Q |
| 03/31/2019 | 05/08/2019 | 10-Q |
| 12/31/2018 | 03/08/2019 | 10-K |
| 09/30/2018 | 11/08/2018 | 10-Q |
| 06/30/2018 | 08/09/2018 | 10-Q |
| 03/31/2018 | 05/04/2018 | 10-Q |
| 12/31/2017 | 03/14/2018 | 10-K |
| 09/30/2017 | 11/09/2017 | 10-Q |
| 06/30/2017 | 08/04/2017 | 10-Q |
| 03/31/2017 | 05/05/2017 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Harrison, Shane R | EVP & Chief Financial Officer | IRA | Buy | 2192026 | 12.27 | 8,000 | 98,162 | 98,162 | Form |
| 2 | Freeman, Jordan Nicole | Chief Accounting Officer | Direct | Buy | 8042025 | 12.97 | 771 | 10,000 | 10,000 | Form |
| 3 | Beans, Patrick E | Direct | Buy | 5132025 | 13.59 | 2,500 | 33,974 | 475,673 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Harrison, Shane R | EVP & Chief Financial Officer | IRA | Buy | 2192026 | 12.27 | 8,000 | 98,162 | 98,162 | Form |
| 2 | Freeman, Jordan Nicole | Chief Accounting Officer | Direct | Buy | 8042025 | 12.97 | 771 | 10,000 | 10,000 | Form |
| 3 | Beans, Patrick E | Direct | Buy | 5132025 | 13.59 | 2,500 | 33,974 | 475,673 | Form |
NRC Health — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.